Genetics of tuberous sclerosis complex: implications for clinical practice.

Area of Science:

• Genetics and Molecular Biology
• Neuroscience
• Pharmacology

Background:

• Tuberous sclerosis complex (TSC) is a multisystem genetic disorder caused by inactivating mutations in either the TSC1 or TSC2 genes.
• These mutations lead to constitutive activation of the mechanistic target of rapamycin (mTOR) signaling pathway in affected tissues.
• TSC affects multiple organ systems, including the brain, skin, lungs, kidneys, and heart, with variable clinical manifestations.

Approach:

• Investigated the role of TSC1/TSC2 protein complex in regulating mTOR signaling.
• Examined the efficacy of mTOR inhibitors, such as rapamycin (sirolimus) and everolimus, in preclinical and clinical settings for TSC.
• Evaluated the impact of mTOR inhibitors on lesion size, organ function, and neurological symptoms in TSC patients.

Key Points:

• Mutations in TSC1 or TSC2 lead to loss of function, resulting in hyperactive mTOR signaling.
• mTOR inhibitors effectively reduce the size of renal and brain lesions associated with TSC.
• These inhibitors demonstrate potential in improving pulmonary function and decreasing seizure frequency in TSC patients.

Conclusions:

• The TSC1/TSC2-mTOR pathway is a critical therapeutic target for Tuberous Sclerosis Complex.
• mTOR inhibitors represent a significant advancement in precision medicine for neurodevelopmental disorders like TSC.
• Targeted inhibition of mTOR signaling offers a promising strategy for managing the diverse clinical manifestations of TSC.